Drug Profile
BIO 10901
Alternative Names: BIO-10901Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator North Carolina State University
- Developer BioMarck Pharmaceuticals
- Class Amino acids; Peptides
- Mechanism of Action Myristoylated alanine rich C kinase substrate inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adult respiratory distress syndrome
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Adult respiratory distress syndrome in USA (Inhalation)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in USA (Inhalation)
- 22 Feb 2016 Preclinical trials in Adult respiratory distress syndrome in USA (Inhalation) prior to February 2016